-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Jim Kelly
Executive Vice President,
Chief Financial Officer and
Treasurer
Chief Financial Officer and
Treasurer
Mr. Kelly is executive vice president, chief financial officer (CFO) and treasurer with responsibility for finance and information technology. He brings more than 25 years of industry experience in both commercial and clinical-stage companies to Novavax.
He joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he spent 10 years at Vanda Pharmaceuticals, where he was CFO and treasurer from 2010-20. From 2000-10, Mr. Kelly served in finance roles of increasing responsibility at MedImmune (now AstraZeneca) and Biogen, most recently as the Vice President and Controller of MedImmune.
Mr. Kelly previously was a member of the corporate finance team at Aetna responsible for mergers and acquisitions and treasury management, and with Janssen, a division of Johnson & Johnson. He holds a Master of Business Administration from Cornell University, a Bachelor of Science in Business Administration from the University of Vermont and is a CFA charterholder.